Cue Biopharma develops injectable treatments that target specific immune cells for autoimmune and inflammatory diseases. It last closed at $2.90 on Nov 17, down 79.43% on the day.
Only 1 firm rated CUE in the past 90 days, not enough for a consensus
Average 12-month target
$83.00
▲ 2762.1% upside
Based on 1 analyst who set a price target on CUE in the past 90 days. The average target is $83.00, with a high of $83.00 and a low of $83.00, compared with the last close of $2.90.
Low $83.00Avg $83.00High $83.00
Blue marker: last close $2.90
Highest target$83.00
Average target$83.00
Lowest target$83.00
Latest rating changes
B. Riley SecuritiesInitiated
Sep 18Buy$83
Date
Firm
Action
Rating
Price target
Sep 18
B. Riley Securities
Initiated
Buy
$83
Loading…
Technical Analysis
CUE · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 524% below its 20 day and 698% below its 50 day average. It is 643% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 20), oversold. The nearest support is the 52 week low at $2.86, and the nearest resistance the Pivot at $6.43.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 105.3%/day
Key levels
$45.5052 week high+1469.0%
$26.25100 day average+805.2%
$23.1350 day average+697.6%
$21.55200 day average+643.1%
$19.54Swing high (Oct 21)+573.8%
$18.1120 day average+524.5%
$9.99Pivot R1+244.5%
$6.43Pivot+121.7%
$2.90Last close
$2.8652 week low−1.4%
Indicators
RSI (14)
20.20
Oversold below 30
Oversold
MACD
-2.78
Below its signal line
Bearish
Stochastic
9.5
Near the bottom of its range
Oversold
ADX (14)
18.0
No clear trend
Williams %R
-99.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-431.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−86.1%
Change over 10 sessions
Bearish
ATR (14)
$3.05
Typical daily range, 105.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 288.0%/day
Key levels
$45.5052 week high+1469.0%
$26.25100 day average+805.2%
$23.1350 day average+697.6%
$21.55200 day average+643.1%
$19.54Swing high (Oct 21)+573.8%
$18.1120 day average+524.5%
$9.99Pivot R1+244.5%
$6.43Pivot+121.7%
$2.90Last close
$2.8652 week low−1.4%
Indicators
RSI (14)
34.12
Weak, oversold below 30
Neutral
MACD
-2.58
Below its signal line
Bearish
Stochastic
5.9
Near the bottom of its range
Oversold
ADX (14)
31.6
Trending down
Williams %R
-99.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-233.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−89.9%
Change over 10 sessions
Bearish
ATR (14)
$8.35
Typical daily range, 288.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CUE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CUE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow CUE usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CUE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CUE is in one of them and how their past CUE trades turned out.
Cue Biopharma is a biopharmaceutical company based in Somerville, Massachusetts, that is developing injectable treatments for autoimmune and inflammatory diseases. Its drug candidates are designed to act on specific immune cells, aiming to calm harmful immune responses while leaving the rest of the immune system largely intact. Its lead program is still in preclinical work, and some of its other candidates have been licensed to outside drugmakers. The company's target patients are people living with these conditions.